

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Please cancel claims 1 – 14 without prejudice.

1 – 14: Cancelled

15. (New) A method for treating cancer in a subject, comprising administering to a subject having cancer (i) a composition of a taxoid molecule conjugated to a water soluble polymer and (ii) radiation.

16. (New) The method of Claim 15, wherein said taxoid is paclitaxel and said water soluble polymer is polyglutamic acid.

17. (New) The method of Claim 15, wherein said taxoid is docetaxel and said water soluble polymer is polyglutamic acid.

18. (New) The method of Claim 16, wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.

19. (New) The method of Claim 18, wherein said polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.

20. (New) The method of Claim 19, wherein said polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.

21. (New) The method of Claim 20, wherein said polyglutamic acid has a molecular weight of about 35,000 daltons.

22. (New) The method of Claim 20, wherein said composition comprises about 37% by weight paclitaxel.

23. (New) The method of Claim 20, wherein said composition comprises from about 2% to about 35% by weight of paclitaxel.

24. (New) The method of Claim 20, wherein said radiation is gamma radiation.
25. (New) The method of Claim 22, wherein said composition is administered prior to said radiation.
26. (New) The method of Claim 22, wherein said composition is administered following said radiation.
27. (New) The method of Claim 22, wherein 14 GY radiation is administered.
28. (New) The method of Claim 22, wherein 7 GY radiation is administered.
29. (New) The method of Claim 22, wherein 10 GY radiation is administered.
30. (New) The method of Claim 29, wherein said 10 GY radiation is administered weekly.
31. (New) The method of Claim 30, wherein 50 to 70 Gray is administered over 5 to 7 weeks.
32. (New) The method of Claim 20, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.
33. (New) The method of Claim 25, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.
34. (New) The method of Claim 26, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.
35. (New) The method of Claim 15, wherein said polymer has a molecular weight of about 20000 to 80000 daltons.

36. (New) The method of Claim 15, wherein said polymer has a molecular weight of about 25000 to 50000 daltons.

37. (New) A method of enhancing the response of a tumor to irradiation, comprising:

a) administering to a patient in need of such therapy a radiosensitizing amount of a pharmaceutical composition comprising paclitaxel, docetaxel, etoposide, teniposide, camptothecin or epothilone conjugated to a water soluble polyamino acid polymer and a pharmaceutically acceptable carrier;

b) irradiating said tumor;

wherein said polymer has a molecular weight of about 5000 to 100000 daltons conjugated paclitaxel or docetaxel have increased water solubility, efficacy and accumulation within a tumor compared with the corresponding unconjugated drugs.

38. (New) The method of claim 37, wherein said polymer is polyglutamic acid having a molecular weight of about 20000 to about 80000 and said conjugate comprises about 2% to about 35% by weight of paclitaxel.

39. (New) The method of claim 37, wherein said polymer is polyglutamic acid having a molecular weight of about 20000 to about 80000 and said conjugate comprises about 2% to about 35% by weight of docetaxel.

REMARKS

Applicants respectfully request that the foregoing amendments be made prior to examination of the present continuation application.

In the specification, paragraphs [0001] and [0018] have been amended. The specification has been amended to update the chain of priority and to make the units for molecular weight consistent with those used in the original claims.

Claims 1-14 are requested to be cancelled, and claims 15-39 are being added. This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, is presented, with an appropriate defined status identifier.

After amending the claims as set forth above, claims 15-39 are now pending in this application.

Respectfully submitted,

Date 19 April 2004

By S. A. Bent

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicants
Registration No. 29,768